On the contrary, inhibitory factors such as PD1, T cell immunoglobulin, mucin domain-containing protein 3 (TIM-3), and Lymphocyte-activation gene 3 (LAG-3), or MDSCs, were reduced in mouse models or murine orthotopic cancer cell lines when PARPis and anti-PD1 were co-administered, leading to a higher ICIs responsivity [48,69,72,81] (Figure 2). This evidence concerns the gene LAG3 and cancer.